This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jaenke, R. S. Articles by Trouet, A. Search for Related Content PubMed PubMed Citation Articles by Jaenke, R. S. Articles by Trouet, A.

Cardiotoxicity and Comparative Pharmacokinetics of Six Anthracyclines in the Rabbit¹

Department of Pathology, Colorado State University, Fort Collins, Colorado 80523 [R. S. J.], and International Institute of Cellular and Molecular Pathology and Universit'e Catholique de Louvain, Bruxelles, Belgium [D. D., A. T.]

Six anthracycline antibiotics with demonstrated antitumor activity in human or experimental tumor systems were studied. The purpose of this investigation was to compare the cardiotoxic potential of these compounds and to characterize the myocardial pharmacokinetics in order to provide a possible explanation for differences in cardiotoxicity. Groups of rabbits received i.v. injections of drug at maximally tolerated treatment doses with respect to lymphohematopoietic toxicity for periods of 11 or 16 weeks and were evaluated histopathologically for the development of myocardial damage. Following a single i.v. administration of the different anthracyclines to rabbits, the amount of parent drug and metabolites accumulating in the heart at various times was determined by high-pressure liquid chromatography and fluorometry.

Adriamycin (ADR), daunorubicin (DNR), and detorubicin produced similar severe cardiomyopathy with frequent congestive heart failure at approximately equal dose levels. Three additional antibiotics, rubidazone and the N-L-leucyl derivatives of ADR and DNR (N-L-leucyl-adriamycin and N-L-leucyl-daunorubicin), produced significantly less severe lymphohematopoietic toxicity, thus permitting the administration of 3 to 3.5 times the ADR and DNR treatment doses. Chronic treatment with these anthracyclines also resulted in significantly less cardiomyopathy, especially in the case of N-L-leucyl-daunorubicin and rubidazone. This reduced cardiomyopathy correlated with lower total myocardial drug accumulation but, more importantly, with lower amounts of DNR or ADR accumulation in the heart. These findings suggest that the degree of anthracycline myocardial toxicity may be directly related to the relative qualitative and quantitative accumulation of drug metabolites in the myocardium.

¹ This work was supported by Rhône-Poulenc, S. A., Paris, France, and by the Fonds Cancerologique de la Caisse Generale d'Epargne et de Retraite, Brussels, Belgium.

² To whom requests for reprints should be addressed.

Received 2/20/80. Accepted 6/25/80.

This article has been cited by other articles:

				V. Dubois, L. Dasnois, K. Lebtahi, F. Collot, N. Heylen, N. Havaux, A.-M. Fernandez, T. J. Lobl, C. Oliyai, M. Nieder, et al. CPI-0004Na, a New Extracellularly Tumor-Activated Prodrug of Doxorubicin: In Vivo Toxicity, Activity, and Tissue Distribution Confirm Tumor Cell Selectivity Cancer Res., April 1, 2002; 62(8): 2327 - 2331. [Abstract] [Full Text] [PDF]

				A. Trouet, A. Passioukov, K. Van derpoorten, A.-M. Fernandez, J. Abarca-Quinones, R. Baurain, T. J. Lobl, C. Oliyai, D. Shochat, and V. Dubois Extracellularly Tumor-activated Prodrugs for the Selective Chemotherapy of Cancer: Application to Doxorubicin and Preliminary in Vitro and in Vivo Studies Cancer Res., April 1, 2001; 61(7): 2843 - 2846. [Abstract] [Full Text]